share_log

4D Pharma (LON:DDDD) Trading Up 5%

4D Pharma (LON:DDDD) Trading Up 5%

4D Pharma(LON:DDDD)股价上涨5%
Financial News Live ·  2022/09/14 12:23

4D pharma plc (LON:DDDD – Get Rating)'s share price was up 5% during trading on Tuesday . The stock traded as high as GBX 16.86 ($0.20) and last traded at GBX 16.66 ($0.20). Approximately 912,370 shares were traded during mid-day trading, a decline of 69% from the average daily volume of 2,957,490 shares. The stock had previously closed at GBX 15.86 ($0.19).

4D Pharma plc(LON:DDDD-GET Rating)的股价在周二的交易中上涨了5%。该股最高交易价格为16.86英镑(0.2美元),最新交易价格为16.66英镑(0.2美元)。午盘成交量约为912,370股,较2,957,490股的日均成交量下降了69%。该股此前的收盘价为15.86英镑(0.19美元)。

4D pharma Stock Up 5.0 %

4D制药类股上涨5.0%

The company has a quick ratio of 4.72, a current ratio of 5.21 and a debt-to-equity ratio of 39.50. The company has a fifty day simple moving average of GBX 16.66 and a 200 day simple moving average of GBX 28.63. The firm has a market capitalization of £30.04 million and a P/E ratio of -1.08.

该公司的速动比率为4.72,流动比率为5.21,债务权益比为39.50。该公司的50日简单移动均线为16.66英镑,200日简单移动均线为28.63英镑。该公司的市值为3004万GB,市盈率为-1.08。

About 4D pharma

关于4D制药

(Get Rating)

(获取评级)

4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease.

4D制药公司及其子公司在英国开发活的生物治疗产品(LBPS)。该公司开发治疗候选药物,包括用于治疗癌症和免疫肿瘤学疾病的MRx0518;用于治疗哮喘的MRx-4DP0004;用于治疗中枢神经系统疾病的MRx0029和MRx0005;用于肠易激综合征的Blautix;以及用于儿童克罗恩病的Thetanix。

Further Reading

进一步阅读

  • This Is What To Expect From The S&P 500 Now
  • The Two Things You Need To Know About Oracle's FQ1 Report
  • Three Value Stocks For A Volatile Market
  • 3 Energy Stocks Nearing Breakouts From Cup-Shaped Patterns
  • Do These Dividend Achievers Deserve A Place In Your Portfolio?
  • 这就是现在对标准普尔500指数的预期
  • 关于甲骨文的FQ1报告,你需要知道的两件事
  • 波动市场的三只价值股
  • 3个能源类股接近突破杯形格局
  • 这些股息获得者值得在你的投资组合中占有一席之地吗?

Receive News & Ratings for 4D pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D pharma and related companies with MarketBeat.com's FREE daily email newsletter.

接受4D药房日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对4D制药及相关公司评级的每日简要摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发